IXHL
Incannex Healthcare, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · AU
$3.64
+1.39%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +63.5%
- EPS
- +98.0%
Three-year CAGR
- Revenue
- -52.2%
- EBITDA
- +15.0%
- EBIT
- +20.8%
- Net income
- —
- EPS
- —
- Free cash flow
- +22.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026